KCS Wealth Advisory’s Amedisys AMED Stock Holding History

KCS Wealth Advisory’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2	Closed	-$262	–	162
2019 Q3	$262	Buy	+2	New	+$260	﹤0.01%	453

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

KCS Wealth Advisory's AMED Position: Q4 2019 in Review

KCS Wealth Advisory sold out of Amedisys (AMED) in Q4 2019, closing a stake of 2 shares — an estimated $262 sold.

KCS Wealth Advisory first reported a position in AMED in Q3 2019 and held it in 1 quarter. The position peaked at $262 in Q3 2019. 325 funds tracked by Wall St. Rank hold AMED as of Q4 2019.

KCS Wealth Advisory reported no remaining Amedisys position as of Q4 2019 after selling out during the quarter.
KCS Wealth Advisory sold 2 Amedisys shares in Q4 2019, an estimated $262.
KCS Wealth Advisory first reported a position in Amedisys in Q3 2019 and held it in 1 quarter.
KCS Wealth Advisory's Amedisys position peaked at $262 in Q3 2019.
325 funds tracked by Wall St. Rank held Amedisys as of Q4 2019.

Based on KCS Wealth Advisory's 13F filing for Q4 2019, filed 15 Jan 2020.